Clinical trials: Allergy; Dermatitis
Atopic Dermatitis (AD)
Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VC005 in Adolescent Subjects With Mild to Moderate Atopic Dermatitis
This is a single arm, and open-label phase I study
- Trial name
- NCT07329101
- Testing
- VC005
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Dermatitis, Atopic
A Study of a Moisturizing Cream and Baby Wash in the Management of Mild to Moderate Atopic Dermatitis in Infants, Toddlers and Children
The purpose of this study is to evaluate the effectiveness (assessed by clinical evaluation of eczema/atopic dermatitis severity and parent-perceived benefits) and tolerability (assessed by clinical grading and parent-perception)…
- Trial name
- NCT04740892
- Testing
- Wash IP, Cream IP
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Dermatitis, Atopic
Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)
The Early Prevention of Asthma in Atopic Children (EPAAC™). 24 months study to evaluate the efficacy and safety of levocetirizine (LCTZ) in preventing the onset of asthma in 12 to 24 months old children.
- Trial name
- NCT00152464
- Testing
- Levocetirizine
- Volunteers
- 514 people
- Sponsor
- UCB Pharma SA
Atopic Dermatitis, Emollients
Double-blind, Randomized, Non-inferiority Trial in Atopic Dermatitis: Comparison of Lipikar Balm and Relipid+ Balm in the Treatment of Mild to Moderate Atopic Dermatitis in Children and Adults
The therapeutic cornerstone for mild to moderate forms of atopic dermatitis (AD) relies on the combination of topical corticosteroids and emollients.
- Trial name
- AIMSI (NCT07358000)
- Testing
- Baume Relipid+
- Where
- France
- Volunteers
- 86 people
- Sponsor
- University Hospital, Caen
Atopic Dermatosis, Alloknesie
Study of Alloknesia in Atopic Dermatitis
Alloknesia is defined as pruritus (= itching) triggered by light mechanical stimuli, which are responsible for the perception of light touch under physiological conditions, but which are perceived as pruritic under pathological…
- Trial name
- ALLOKNESIE (NCT06923202)
- Where
- 8 sites in France
- Volunteers
- 160 people
- Sponsor
- University Hospital, Brest
Atopic Dermatitis
Human Testing of an Over-the-Counter (OTC) Cream in Children With Eczema
This three week study will be conducted to determine the safety and efficacy of an over-the-counter (OTC) cream in children with mild to moderate atopic dermatitis.
- Trial name
- NCT01326910
- Testing
- Colloidal Oatmeal, Topical Cream
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc.
Sensitivity, Contact
Dermatological Assessment of Primary Dermal Irritability Accumulated and Sensitization
This is a clinical study for health care product safety assessment. The research will be conducted with 92 subjects, aged 18 to 59 years.
- Trial name
- NCT04248556
- Testing
- Health care product
- Where
- Brazil
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Herbarium Laboratorio Botanico Ltda
Atopic Dermatitis
Study of KHK 4323 in Healthy Volunteers and Subjects With Atopic Dermatitis
Part 1: To investigate the safety and tolerability of intravenous (IV) or subcutaneous (SC) administration of a single dose of KHK4323 to Japanese or Caucasian healthy adult males in a double-blind, placebo-controlled study.
- Trial name
- NCT03846466
- Testing
- KHK4323 IV/S, KHK4323 SC/S, KHK4323 IV/M
- Where
- Japan
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Co., Ltd.
Dermatitis, Atopic
Phase IIa Study of WBI-1001 Cream for Atopic Dermatitis
WBI-1001 is a synthetic,new, non-steroid, small molecule being developed as a candidate drug for the topical, cream treatment of inflammatory skin diseases.
- Trial name
- WBI-1001-201 (NCT00837551)
- Testing
- WBI-1001
- Where
- Canada
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Welichem Biotech Inc.
Dermatitis, Atopic
Results in Real Clinical Practice of Treatment of Moderate-severe Atopic Dermatitis
The purpose of this study is to determine the efficacy results in terms of percentage improvement of the Eczema Area and Severity Index (EASI) as well as on the scale Patient Global Assessment (PGA) throughout the follow-up of…
- Trial name
- Dermatitis (NCT05078294)
- Where
- 7 sites in Spain
- Volunteers
- 300 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Atopic Dermatitis
Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis
This is a randomized, double-blind, vehicle-controlled, Phase 2 study in subjects with moderate AD.
- Trial name
- NCT03824405
- Testing
- BTX 1204, Vehicle
- Where
- 31 sites in United States, Australia and 1 more
- Volunteers
- 200 people
- Sponsor
- Botanix Pharmaceuticals
Dermatitis, Atopic
A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated
The primary objective of this trial is to investigate the safety, tolerability and efficacy of BI 655130 in patients with Atopic Dermatitis (AD) following repeated intravenous administrations compared to placebo.
- Trial name
- NCT03822832
- Testing
- BI 655130
- Where
- 23 sites in United States, Canada and 1 more
- Volunteers
- 51 people
- Sponsor
- Boehringer Ingelheim
Atopic Dermatitis
A Phase 2 Study of CIM331 for Atopic Dermatitis Patients
To assess the safety, tolerability and efficacy of CIM331, compared to placebo, in atopic dermatitis patients who are inadequately controlled by or intolerant to topical therapy
- Trial name
- NCT01986933
- Testing
- nemolizumab (CIM331)
- Where
- 18 sites in United States
- Volunteers
- 264 people
- Sponsor
- Chugai Pharmaceutical
Atopic Dermatitis
A Phase 1 Trial of OPA-15406 Ointment in Healthy Adult Male Subjects
To assess the safety (especially skin findings) and pharmacokinetics by applying 0.3%, 1%, or 3% formulation of 5g OPA-15406 ointment to a 1000 cm2 area as a single-dose and as a multiple-dose twice daily for 2 weeks in Japanese…
- Trial name
- NCT02334787
- Testing
- 0.3% OPA-15406 Ointment, 1% OPA-15406 Ointment, 3% OPA-15406 Ointment
- Where
- Japan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Atopic Dermatitis, Psoriasis
Skin Microbial Ecology in Atopic Dermatitis
Everybody's skin has bacteria that normally lives on it. Previous research has shown that people with eczema (or atopic dermatitis [AD]) have much higher concentrations of a certain bacteria (S.
- Conditions
- Atopic Dermatitis, Psoriasis, Healthy
- Trial name
- NCT04170244
- Testing
- AD subject visit sampling procedures, PS subject visit sampling procedures, Healthy control visit sampling procedures
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Atopic Dermatitis, Atopic Dermatitis (AD)
Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica
The goal of this observational registry is to characterize the clinical features, severity, treatments, and outcomes of patients with atopic dermatitis in Costa Rica receiving systemic and advanced therapies in routine clinical…
- Conditions
- Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema), Atopic Dermatitis Patients
- Trial name
- NCT07448363
- Testing
- Abrocitinib, Upadacitinib, Baricitinib
- Where
- Costa Rica
- Volunteers
- 50 people
- Sponsor
- Caja Costarricense de Seguro Social
Atopic Dermatitis
A Study Evaluating TRIV-573 in Atopic Dermatitis
The goal of this interventional study is to learn if TRIV-573 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-573.
- Trial name
- NCT07782333
- Testing
- TRIV-573
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 90 people
- Sponsor
- Triveni Bio
Atopic Dermatitis
Extension Study of Pimecrolimus Cream in Pediatric Patients With Atopic Dermatitis
Pimecrolimus, which is an ascomycin derivative, is an anti-inflammatory non-steroidal agent. In this study, the long-term safety and efficacy of Pimecrolimus cream will be evaluated in Japanese pediatric patients with atopic…
- Trial name
- NCT00231998
- Testing
- Pimecrolimus
- Where
- Japan
- Volunteers
- 240 people
- Sponsor
- Novartis
Dermatitis, Atopic
Efficacy and Tolerability of HAT1 in Patients With Moderate to Severe Atopic Dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by a disturbance of epidermal-barrier function that results in intensely pruritic subacute and chronic eczematous plaques.
- Trial name
- NCT03059693
- Testing
- HAT1 topical cream, Vehicle cream
- Volunteers
- 48 people
- Sponsor
- Haus Bioceuticals
Autoimmune Diseases, Inflammatory Disease
In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases
Interleukin 2 (IL-2) is a critical cytokine for the survival and function of regulatory T cells (LTreg). This cytokine has a dual role in the immune system.
- Conditions
- Autoimmune Diseases, Inflammatory Disease, Acquired Bone Marrow Aplasia, Systemic Lupus Erythematosus
- Trial name
- MuTreg (NCT05544448)
- Testing
- Blood sample taken at a single time point
- Where
- France
- Volunteers
- 67 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.